In the Spirit of the Doha Declaration

It is half a decade since the Doha Declaration. The declaration states that developing countries must use public health safeguards written into the World Trade Organization’s intellectual properties rules to access less expensive, generic versions of patented medicines.
How come then Novartis instituted a lawsuit against a company in India for producing generics of the anticancer drug, Glivec? The generic costs about $2,700 yearly per patient while Glivec costs $27,000 for the same time period.
Pfizer is fighting the Philippines government for approving a generic of the antihypertensive, Norvasc. The generic costs 90% less.
Oxfam International released a report recently stating that rich countries have broken the spirit of the Doha Declaration (see www. Oxfam.org for a copy of the report, Patents versus Patients: Five Years after the Doha Declaration). The report states that many wealthy countries go to great lengths to protect medicine patents putting profits before patients. As a result, patented medicines continue to be priced out of the reach of the world’s poorest people.
It is instructive to remember that the burden of disease continues to rise especially in poor countries. For instance, between 2001 and 2005, more than 4 million people became newly infected with HIV in developing countries. Yet, 74% of AIDS medicines are still under monopoly, 77% of Africans have no access to AIDS treatment and 30% of the world’s population does not have access to essential medicines.
In the spirit of the Doha Declaration, the Oxfam report concluded with some recommendations which I agree with and summarize in my own words below:
1. Wealthy countries should live up to their promise and relax the strict intellectual properties laws as regards patented medicines.
2. Rich countries should muster the political will to provide technical support that will enhance universal access to essential medicines
3. Leaders in developing countries should become responsible and explore, with a view to invoking, the “public health safeguards written into the WTO’s intellectual property rules” in order to abolish differential access to medicines.
4. Pfizer and Norvatis should, if not in the spirit of the declaration, for the sake of corporate social responsibility, end their feud with developing countries.

His Excellency’s ludicrous Elixir for AIDS

Last weekend, I sat glued to my TV set watching CNN Jeff Koinange’s exposé on the AIDS situation in the Gambia, one of the poorest nations of the world.
I was flustered by the claims being made. I still am.
His Excellency, the President of the Gambia, Yahya Jammeh, had invited the CNN team to come and see the wonders being wrought by an herbal concoction he had personally formulated for the treatment and cure of AIDS. The constituents of the concoction were revealed to him in a dream!
Many Gambians have already abandoned their HAART for this miracle cure and the risk for resistance will certainly skyrocket because many antiretroviral agents are unsparing.
CNN’s repeated efforts to interview the president failed and attempts to subject the concoction to standard scientific testing met a brick wall. An expatriate who spoke out against the president’s farcical claims was thrown out of the country within 48 hours. Even more disheartening is the fact that the health minister, a physician trained in the West, swore on set that the concoction can cure AIDS.
What is wrong with Africa?
Why has his Excellency forgotten so soon similar claims made by Thabo Mbeki and the former South African health minister? Did his Excellency ever hear of Nigeria’s Dr Abalaka? Why return to ideas and claims that belong in the Stone Age? Why belittle the threat of a scourge currently devastating us, the world’s poor? Why would the Gambia, a country with a Medical Research Council which is home to prolific, world-renowned researchers drag Africa backward in her quest to see the end of AIDS?
Why?